Fresenius SE Had Testing Issues Like Akorn's, Executive Says -Bloomberg
13 Juli 2018 - 11:31AM
Dow Jones News
--A Fresenius SE & Co. executive has said his company
experienced testing problems similar to those that Fresenius cited
as grounds for pulling out of a $4.3 billion deal to buy U.S.
generic-drug maker Akorn Inc., Bloomberg reports.
--Mats Henriksson testified on Thursday in Delaware that it took
Fresenius two years to address questions raised by the U.S. Food
and Drug Administration in 2013 regarding drug-injection testing
and test-result storage at a Fresenius plant in India, Bloomberg
said.
Full story: https://bloom.bg/2Jj178B
Write to Barcelona editors at barcelonaeditors@dowjones.com
(END) Dow Jones Newswires
July 13, 2018 05:16 ET (09:16 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Akorn (NASDAQ:AKRX)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
Von Mär 2023 bis Mär 2024
Echtzeit-Nachrichten über Akorn Inc (NASDAQ): 0 Nachrichtenartikel
Weitere Akorn, Inc. News-Artikel